News
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...
Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
The stock's fall snapped a three-day winning streak.
Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...
Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Zacks Investment Research on MSN15h
Here's Why Merck (MRK) Fell More Than Broader MarketMerck (MRK) ended the recent trading session at $80.32, demonstrating a -1.27% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.27%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback